ARTICLE | Financial News
Versant launches Tempest with $70M
March 28, 2018 11:04 AM UTC
Immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) emerged from Versant Ventures' Inception Sciences Inc. incubator with a tranched $70 million series B led by Versant, F-Prime Capital and Quan Capital. Lilly Asia Ventures, Foresite Capital and Eight Roads Ventures also participated. Details regarding the tranches were not disclosed.
Tempest is the first disclosed newco from Inception that does not follow the build-to-buy model (see BioCentury, March 28)...